PDUFA dates June 2024: FDA calendar and catalysts.
1 PDUFA date fell in June 2024: ZUSDURI (Jun 2024). The FDA calendar also recorded 56 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.
PDUFA dates in June 2024
| PDUFA date | Company | Ticker | Drug | Indication | Source |
|---|---|---|---|---|---|
| Jun 2024 | UroGen Pharma Ltd. | URGN | ZUSDURI (mitomycin) | SEC 8-K Exhibit 99.1, filed 2025-01-14 |
Download: CSV · JSON · iCal (next 30 days, CC BY 4.0) · Calendar API · All months
June 2024: other FDA decisions and filings
June 2024: dated readouts
| Date | Drug | Company | Event | Indication | Status | Source |
|---|---|---|---|---|---|---|
| Jun 2024Month disclosed | — | ABBV | Topline readout | — | Positive | SEC Form 10-K |
| Jun 2024Month disclosed | AMVUTTRA® (vutrisiran) | ALNY | Topline readout | ATTR amyloidosis with cardiomyopathy | Positive | SEC Form 10-K |
| Jun 2024Month disclosed | UPLIZNA® (inebilizumab) | AMGN | Topline readout | Immunoglobulin G4-related disease | Positive | SEC Form 10-K |
| Jun 2024Month disclosed | Anaphylm™ (dibutepinephrine) | AQST | Topline readout | — | Positive | SEC Form 10-Q |
| Jun 2024Month disclosed | CardiolRx™ (cardiolrx) | CRDL | Topline readout | — | Positive | SEC 8-K Exhibit 99.1 |
| Jun 2024Month disclosed | — | CRDL | Topline readout | — | Positive | SEC 8-K Exhibit 99.1 |
| Jun 2024Month disclosed | CRD-38 | CRDL | Topline readout | — | Positive | SEC 8-K Exhibit 99.1 |
| Jun 2024Month disclosed | itolizumab (EQ001) | EQ | Topline readout | alopecia areata, or AA, and in June 2024, we | Positive | SEC Form 10-Q |
| Jun 2024Month disclosed | aleniglipron (GSBR-1290) | GPCR | Topline readout | — | Met primary endpoint | SEC Form 10-Q |
| Jun 2024Month disclosed | imatinib (IKT-001) | IKT | Topline readout | — | Missed primary endpoint | SEC Form 10-K |
| Jun 2024Month disclosed | — | MIRM | Interim readout | — | Met primary endpoint | SEC 8-K Exhibit 99.1 |
| Jun 2024Month disclosed | licaminlimab (OCS-02) | OCS | Topline readout | signs and symptoms of moderate to severe DED | Positive | SEC 8-K Exhibit 99.1 |
| Jun 2024Month disclosed | divesiran (SLN124) | SLN | Interim readout | — | Positive | SEC 8-K Exhibit 99.1 |
| Jun 2024Month disclosed | — | SVRA | Topline readout | — | Positive | sec_424b |
| June 25, 2024 | IGALMI® (dexmedetomidine) | BTAIQ | Topline readout | — | Positive | SEC Form 10-Q |
June 2024: trial starts and primary completions
| Date | Drug | Company | Event | Indication | Status | Source |
|---|---|---|---|---|---|---|
| Jun 2024Month disclosed | clofazimine (MNKD-101) | MNKD | Trial start | — | Completed | SEC Form 10-K |
| Jun 2024Month disclosed | DB-1305 | BNTX | Trial start | — | Completed | SEC 8-K Exhibit 99.1 |
| Jun 2024Month disclosed | VS-7375 | VSTM | Trial start | — | Completed | SEC Form 8-K |
| Jun 2024Month disclosed | LTSE-2578 | GPCR | Trial start | idiopathic pulmonary fibrosis | Completed | SEC Form 10-Q |
| Jun 2024Month disclosed | HMPL-506 | HCM | Trial start | hematological malignancies | Completed | SEC Form 10-K |
| Jun 2024Month disclosed | TH103 | KLRS | Trial start | — | Completed | SEC 8-K Exhibit 99.1 |
| Jun 2024Month disclosed | KPL-387 | KNSA | Trial start | — | Completed | SEC Form 10-Q |
| Jun 2024Month disclosed | KEYTRUDA® (pembrolizumab) | MRNA | Trial start | — | Completed | SEC Form 10-K |
| Jun 2024Month disclosed | SPY001 | SYRE | Trial start | — | Completed | SEC Form 10-Q |
| Jun 2024Month disclosed | TRB-051 | TRXB | Trial start | — | Completed | sec_424b |
| Jun 2024Month disclosed | IPH6501 | IPHA | Trial start | — | Completed | SEC 8-K Exhibit 99.1 |
2 more milestones are guided to a half-year or full-year window, or estimated from ClinicalTrials.gov primary completion dates, that overlaps June 2024. They are on each drug page and in the calendar API.
Questions
What PDUFA dates are in June 2024?
1 PDUFA date fell in June 2024: ZUSDURI (Jun 2024). The FDA calendar also recorded 56 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.
Can these dates change?
Yes. The FDA can extend a review by three months after a major amendment, and it sometimes acts before the goal date. Each row links the filing the date came from.
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.